Strativa Pharmaceuticals Announces FDA Approval of Nascobal
(Cyanocobalamin, USP) Nasal Spray
ResourcesBlogJournalists
Log InSign UpSend a Release
NewsProductsContact
Search
Advanced Search
News in Focus
Browse News Releases
All News Releases
News Releases OverviewEnglish-onlyAll Public Company
Multimedia Gallery
All Multimedia
Multimedia Gallery OverviewAll PhotosAll Videos
Trending Topics
All Trending Topics
Business & Money
Auto & Transportation
All Auto & Transportation
Auto & Transportation OverviewAerospace, DefenseAir
FreightAirlines & AviationAutomotiveMaritime &
ShipbuildingRailroads and Intermodal TransportationTransportation,
Trucking & RailroadTravelTrucking and Road Transportation
Business Technology
All Business Technology
Business Technology OverviewBlockchainBroadcast TechComputer
HardwareComputer SoftwareComputer & ElectronicsData
AnalyticsElectronic CommerceElectronic ComponentsElectronic Design
AutomationFinancial TechnologyHigh Tech SecurityInternet
TechnologyNanotechnologyNetworksPeripheralsSemiconductors
Entertainment & Media
All Entertainment & Media
Entertainment & Media
OverviewAdvertisingArtBooksEntertainmentFilm and Motion
PictureMagazinesMusicPublishing & Information
ServicesRadioTelevision
Financial Services & Investing
All Financial Services & Investing
Financial Services & Investing OverviewAccounting News &
IssuesAcquisitions, Mergers and TakeoversBanking & Financial
ServicesBankruptcyBond & Stock RatingsConference Call
AnnouncementsContractsDividendsEarnings Forecasts &
ProjectionsEarningsFinancing AgreementsInsuranceInvestments
OpinionsJoint VenturesMutual FundsPrivate PlacementReal
EstateRestructuring & RecapitalizationSales ReportsShareholder
ActivismStock OfferingStock SplitVenture Capital
General Business
All General Business
General Business OverviewAgency RosterAwards Commercial Real
EstateCorporate ExpansionEarningsHuman Resource & Workforce
ManagementLicensingNew Products & ServicesObituariesOutsourcing
BusinessesOverseas Real Estate (non-US)Personnel AnnouncementsReal
Estate TransactionsResidential Real EstateSmall Business
ServicesSocially Responsible InvestingSurveys, Polls and
ResearchTrade Show News
Science & Tech
Consumer Technology
All Consumer Technology
Consumer Technology OverviewBlockchainComputer
ElectronicsComputer HardwareComputer SoftwareConsumer
ElectronicsData AnalyticsElectronic CommerceElectronic
GamingFinancial TechnologyMobile EntertainmentMultimedia &
InternetPeripheralsSTEM (Science, Tech, Engineering, Math)Social
MediaWireless Communications
Energy
All Energy
Energy OverviewAlternative EnergiesChemicalElectrical
UtilitiesGasMiningMining & MetalsOil & EnergyOil and Gas
DiscoveriesUtilitiesWater Utilities
Environment
All Environment
Environment OverviewConservation & RecyclingEnvironmental
IssuesEnvironmental PolicyEnvironmental Products &
ServicesGreen TechnologyNatural Disasters
Heavy Industry & Manufacturing
All Heavy Industry & Manufacturing
Heavy Industry & Manufacturing OverviewAerospace &
DefenseAgricultureChemicalConstruction & BuildingHVAC (Heating,
Ventilation and Air-Conditioning)Machine Tools, Metalworking and
MetallurgyMachineryMiningMining & MetalsPaper, Forest Products
& ContainersPrecious MetalsTextilesTobacco
Telecommunications
All Telecommunications
Telecommunications OverviewCarriers and ServicesMobile
EntertainmentNetworksPeripheralsTelecommunications
EquipmentTelecommunications IndustryVoIP (Voice over Internet
Protocol)Wireless Communications
Lifestyle & Health
Consumer Products & Retail
All Consumer Products & Retail
Consumer Products & Retail OverviewAnimals & PetsBeers,
Wines and SpiritsBeveragesBridal ServicesCannabisCosmetics and
Personal CareFashionFood & BeveragesFurniture and
FurnishingsHome ImprovementHousehold ProductsHousehold, Consumer
& CosmeticsJewelryNon-Alcoholic BeveragesOffice ProductsOrganic
FoodProduct RecallsRestaurantsRetailSupermarketsToys
Entertainment & Media
All Entertainment & Media
Entertainment & Media
OverviewAdvertisingArtBooksEntertainmentFilm and Motion
PictureMagazinesMusicPublishing & Information
ServicesRadioTelevision
Health
All Health
Health OverviewBiometricsBiotechnologyDentistryClinical Trials
& Medical DiscoveriesFDA ApprovalHealth Care &
HospitalsHealth InsuranceInfection ControlMedical EquipmentMedical
PharmaceuticalsMental HealthPharmaceuticalsSupplementary
Medicine
Sports
All Sports
Sports OverviewGeneral SportsOutdoors, Camping &
HikingSporting EventsSports Equipment & Accessories
Travel
All Travel
Travel OverviewAmusement Parks and Tourist AttractionsGambling
& CasinosHotels and ResortsOutdoors, Camping &
HikingPassenger AviationTravel Industry
Policy & Public Interest
Policy & Public Interest
All Policy & Public Interest
Policy & Public Interest OverviewAdvocacy Group
OpinionAnimal WelfareCorporate Social ResponsibilityDomestic
PolicyEconomic News, Trends, AnalysisEducationEnvironmentalEuropean
GovernmentFDA ApprovalFederal and State LegislationFederal
Executive Branch & AgencyForeign Policy & International
AffairsHomeland SecurityLabor & UnionLegal IssuesNatural
DisastersNot For ProfitPatent LawPublic SafetyTrade PolicyU.S.
State Policy
People & Culture
People & Culture
All People & Culture
People & Culture OverviewAboriginal, First Nations &
Native AmericanAfrican AmericanAsian AmericanChildrenDisabilities,
Disabled PeopleHispanicLesbian, Gay & BisexualReligionSenior
CitizensVeteransWomen
In-Language News
espaolportuguseskoDanmarkDeutschlandEspaaFranceItaliaNederlandNorgePolskaPortugalSlovenskoSverigeSuomi
OverviewMarketingPublic RelationsIR & ComplianceAgencyAll
Products
General Inquiries Request a Demo Editorial Bureaus Partnerships
Media Inquiries Worldwide Offices
Strativa Pharmaceuticals Announces FDA Approval of Nascobal
(Cyanocobalamin, USP) Nasal Spray Single-Use Device
One Spray per Device, Without the Need for Priming, Provides
Greater Ease of Use
Jun 10, 2014, 14:34 ET from Par Pharmaceutical Companies,
Inc.
WOODCLIFF LAKE, N.J., June 10, 2014 /PRNewswire/ --Strativa
Pharmaceuticals, the branded division of Par Pharmaceutical
Companies, Inc., today announced that the U.S. Food and Drug
Administration has approved Nascobal Nasal Spray in a single-use
device. Nascobal is a prescription vitamin B12 supplement
administered as one spray, one nostril, once a week. Each
single-use device delivers one spray of 500 mcg of cyanocobalamin,
USP. Unlike the current multi-use glass bottle with actuator pump,
no priming is required with the new single-use device, which
delivers a precise dose upon administration. A carton of four
single-use devices provides patients with a convenient one month
supply of Nascobal. Nascobal Nasal Spray is indicated for the
maintenance of normal hematologic status in pernicious anemia
patients who are in remission following intramuscular vitamin B12
therapy and who have no nervous system involvement. Nascobal Nasal
Spray is also indicated as a supplement for other vitamin B12
deficiencies. Refer to full prescribing information for Indications
and Usage at www.nascobal.com
"Unlike the current device, our new Nascobal single-use device
does not require priming, which eliminates product loss. In
addition, it permits patients to conveniently receive their dose
with one spray per disposable device," said Rick Painter, Senior
Vice President, Brand Sales and Marketing. "Strativa remains
committed to improving the product experience of the patients who
rely upon us," Mr. Painter said.
The new Nascobal Nasal Spray single-use device requires no
assembly and simplifies the tracking of dose administration. The
disposable single-use device is hygienic, portable and will replace
the currently available multi-use product. It will be available in
pharmacies in September. Strativa is continuing the development of
new and enhanced versions of Nascobal in order to better meet the
needs of those patients who rely upon the product.
Important Information About Nascobal Nasal Spray
Nascobal Nasal Spray is contraindicated in patients with
sensitivity to cobalt and/or vitamin B12 or any component of the
medication. Patients with pernicious anemia should be instructed
that they will require weekly administration of Nascobal for the
rest of their lives. If a patient is not properly maintained with
Nascobal Nasal Spray, intramuscular vitamin B12 is necessary.
Vitamin B12 concentrations must be monitored. Patients with early
Leber's disease (hereditary optic nerve atrophy) who were treated
with vitamin B12 suffered severe and swift optic nerve atrophy.
Vitamin B12 deficiency may suppress signs of polycythemia vera.
Treatment with vitamin B12 may mask this condition. Hypokalemia and
sudden death may occur in severe megaloblastic anemia which is
treated intensely with vitamin B12. Side effects thought to be
related to Nascobal are usually mild and include headache, nausea,
and rhinitis. Refer to full prescribing information for Warnings
and Precautions at www.nascobal.com
About Par Pharmaceutical Companies, Inc.
Par Pharmaceutical Companies, Inc. is a privately held,
U.S.-based specialty pharmaceutical company that develops,
manufactures and markets high barrier-to-entry generic drugs and
niche, innovative proprietary pharmaceuticals through its
wholly-owned subsidiary's two operating divisions, Par
Pharmaceutical and Strativa Pharmaceuticals. For press release and
other company information, visit www.parpharm.com.
About Strativa Pharmaceuticals
Strativa Pharmaceuticals, the proprietary products division of a
wholly owned subsidiary of Par Pharmaceutical Companies, Inc.,
excels at finding, enhancing and bringing to market drugs that make
a meaningful difference to patients. For more information about
Strativa, visit www.strativapharma.com
SOURCE Par Pharmaceutical Companies, Inc.
RELATED LINKS
http://www.parpharm.com
View Table Fullscreen
View Table Fullscreen
Journalists and Bloggers
The news you need, when you need it.
Join PR Newswire for Journalists to access all of the free
services designated to make your job easier.
In need of subject matter experts for your story? Submit a free
ProfNet request and find the sources you need.
LEARN MORE
Aug 06, 2014, 10:54 ET
Preview: Par Pharmaceutical Announces Quarterly Conference
Call
May 07, 2014, 11:34 ET
Preview: Par Pharmaceutical Announces Quarterly Conference
Call
Release contains wide tables. View fullscreen.
Looking to send a news release with PR Newswire?
Take advantage of the world's leading distribution platform.
Sign up to get started
Request more information
Have an account? Log In
Send a Release
Phone 8AM - 10PM ET
+1-888-776-0942
Send a ReleaseSign UpResourcesBlogJournalists
Search
Searching for your content...
Advanced Search
Share this article
Contact PR Newswire
888-776-0942from 8 AM - 10 PM ET
Contact Us General InquiriesRequest a DemoEditorial
BureausPartnershipsMedia InquiriesWorldwide Offices
Products Cision Communications Cloud For Marketers For Public
Relations For IR & Compliance For Agency For Small Business All
Products
About About PR Newswire About Cision Become a Publishing Partner
Become a Channel Partner Careers Global Sites
AsiaBrazilCanadaCzechDenmarkFinlandFranceGermanyIndiaIsraelMexicoMiddle
EastNetherlandsNorwayPolandPortugalRussiaSlovakiaSpainSwedenUnited
Kingdom
My Services All News Releases Online Member Center ProfNet
My Services All News ReleasesOnline Member CenterProfNet
888-776-0942from 8 AM - 10 PM ET
Terms of UsePrivacy PolicyInformation Security Policy
StatementSite MapRSS Feeds
Copyright 2018 PR Newswire Association LLC. All Rights Reserved.
A Cision company.
News ProductsContacts
News in Focus
Browse News Releases
All News Releases
News Releases OverviewEnglish-onlyAll Public Company
Multimedia Gallery
All Multimedia
Multimedia Gallery OverviewAll PhotosAll Videos
Trending Topics
All Trending Topics
Business & Money
Auto & Transportation
All Auto & Transportation
Auto & Transportation OverviewAerospace, DefenseAir
FreightAirlines & AviationAutomotiveMaritime &
ShipbuildingRailroads and Intermodal TransportationTransportation,
Trucking & RailroadTravelTrucking and Road Transportation
Business Technology
All Business Technology
Business Technology OverviewBlockchainBroadcast TechComputer
HardwareComputer SoftwareComputer & ElectronicsData
AnalyticsElectronic CommerceElectronic ComponentsElectronic Design
AutomationFinancial TechnologyHigh Tech SecurityInternet
TechnologyNanotechnologyNetworksPeripheralsSemiconductors
Entertainment & Media
All Entertainment & Media
Entertainment & Media
OverviewAdvertisingArtBooksEntertainmentFilm and Motion
PictureMagazinesMusicPublishing & Information
ServicesRadioTelevision
Financial Services & Investing
All Financial Services & Investing
Financial Services & Investing OverviewAccounting News &
IssuesAcquisitions, Mergers and TakeoversBanking & Financial
ServicesBankruptcyBond & Stock RatingsConference Call
AnnouncementsContractsDividendsEarnings Forecasts &
ProjectionsEarningsFinancing AgreementsInsuranceInvestments
OpinionsJoint VenturesMutual FundsPrivate PlacementReal
EstateRestructuring & RecapitalizationSales ReportsShareholder
ActivismStock OfferingStock SplitVenture Capital
General Business
All General Business
General Business OverviewAgency RosterAwards Commercial Real
EstateCorporate ExpansionEarningsHuman Resource & Workforce
ManagementLicensingNew Products & ServicesObituariesOutsourcing
BusinessesOverseas Real Estate (non-US)Personnel AnnouncementsReal
Estate TransactionsResidential Real EstateSmall Business
ServicesSocially Responsible InvestingSurveys, Polls and
ResearchTrade Show News
Science & Tech
Consumer Technology
All Consumer Technology
Consumer Technology OverviewBlockchainComputer
ElectronicsComputer HardwareComputer SoftwareConsumer
ElectronicsData AnalyticsElectronic CommerceElectronic
GamingFinancial TechnologyMobile EntertainmentMultimedia &
InternetPeripheralsSTEM (Science, Tech, Engineering, Math)Social
MediaWireless Communications
Energy
All Energy
Energy OverviewAlternative EnergiesChemicalElectrical
UtilitiesGasMiningMining & MetalsOil & EnergyOil and Gas
DiscoveriesUtilitiesWater Utilities
Environment
All Environment
Environment OverviewConservation & RecyclingEnvironmental
IssuesEnvironmental PolicyEnvironmental Products &
ServicesGreen TechnologyNatural Disasters
Heavy Industry & Manufacturing
All Heavy Industry & Manufacturing
Heavy Industry & Manufacturing OverviewAerospace &
DefenseAgricultureChemicalConstruction & BuildingHVAC (Heating,
Ventilation and Air-Conditioning)Machine Tools, Metalworking and
MetallurgyMachineryMiningMining & MetalsPaper, Forest Products
& ContainersPrecious MetalsTextilesTobacco
Telecommunications
All Telecommunications
Telecommunications OverviewCarriers and ServicesMobile
EntertainmentNetworksPeripheralsTelecommunications
EquipmentTelecommunications IndustryVoIP (Voice over Internet
Protocol)Wireless Communications
Lifestyle & Health
Consumer Products & Retail
All Consumer Products & Retail
Consumer Products & Retail OverviewAnimals & PetsBeers,
Wines and SpiritsBeveragesBridal ServicesCannabisCosmetics and
Personal CareFashionFood & BeveragesFurniture and
FurnishingsHome ImprovementHousehold ProductsHousehold, Consumer
& CosmeticsJewelryNon-Alcoholic BeveragesOffice ProductsOrganic
FoodProduct RecallsRestaurantsRetailSupermarketsToys
Entertainment & Media
All Entertainment & Media
Entertainment & Media
OverviewAdvertisingArtBooksEntertainmentFilm and Motion
PictureMagazinesMusicPublishing & Information
ServicesRadioTelevision
Health
All Health
Health OverviewBiometricsBiotechnologyDentistryClinical Trials
& Medical DiscoveriesFDA ApprovalHealth Care &
HospitalsHealth InsuranceInfection ControlMedical EquipmentMedical
PharmaceuticalsMental HealthPharmaceuticalsSupplementary
Medicine
Sports
All Sports
Sports OverviewGeneral SportsOutdoors, Camping &
HikingSporting EventsSports Equipment & Accessories
Travel
All Travel
Travel OverviewAmusement Parks and Tourist AttractionsGambling
& CasinosHotels and ResortsOutdoors, Camping &
HikingPassenger AviationTravel Industry
Policy & Public Interest
Policy & Public Interest
All Policy & Public Interest
Policy & Public Interest OverviewAdvocacy Group
OpinionAnimal WelfareCorporate Social ResponsibilityDomestic
PolicyEconomic News, Trends, AnalysisEducationEnvironmentalEuropean
GovernmentFDA ApprovalFederal and State LegislationFederal
Executive Branch & AgencyForeign Policy & International
AffairsHomeland SecurityLabor & UnionLegal IssuesNatural
DisastersNot For ProfitPatent LawPublic SafetyTrade PolicyU.S.
State Policy
People & Culture
People & Culture
All People & Culture
People & Culture OverviewAboriginal, First Nations &
Native AmericanAfrican AmericanAsian AmericanChildrenDisabilities,
Disabled PeopleHispanicLesbian, Gay & BisexualReligionSenior
CitizensVeteransWomen
In-Language News
espaolportuguseskoDanmarkDeutschlandEspaaFranceItaliaNederlandNorgePolskaPortugalSlovenskoSverigeSuomi
Phone
888-776-0942 from 8 AM - 10 PM ET
Chat
All contact info
Send a Release Log In
